Interact with experts and peers.

Recent Posts

10 of 43 Shown
  • Using Ledipasvir/Sofosbuvir in Cirrhotic, Treatment-Experienced GT1 Patients: 12 Weeks With Ribavirin or 24 Weeks Without?

    Ira M. Jacobson MD - 3/23/2015
    Although new data suggest comparable efficacy of ledipasvir/sofosbuvir with ribavirin for 12 weeks vs 24 weeks without ribavirin in genotype 1 cirrhotic, treatment-experienced patients, I am not convinced that shortening treatment is the best approach.
  • Improving Access to HCV Treatment: The Clinician’s Role

    Norah Terrault MD, MPH - 3/13/2015 1 comment / Last Comment: 3/19/2015
    In the current era of HCV therapy, my evaluation of patients now includes more comprehensive screening for extrahepatic disease manifestations and cofactors.
  • Genotype 3 HCV: Still Difficult to Treat?

    Jordan J. Feld MD, MPH - 2/10/2015 1 comment / Last Comment: 2/25/2015
    My take on how to manage genotype 3 HCV and how evolving therapeutic options will likely improve outcomes for treatment-experienced cirrhotic patients with genotype 3 HCV infection.
  • Looking Beyond Liver Disease Stage When Determining Need for HCV Therapy

    Mark S. Sulkowski MD - 12/31/2014 10 comments / Last Comment: 3/8/2015
    Coverage of treatment was recently denied for my 23-year-old patient interested in starting therapy to prevent mother-to-child HCV transmission.
  • How I Manage Drug Interactions When Using New All-Oral DAA Regimens in Patients With HIV/HCV Coinfection

    Mark S. Sulkowski MD - 12/29/2014 2 comments / Last Comment: 1/21/2015
    With a new generation of all-oral HCV therapies entering clinical practice, keeping alert to potential interactions with antiretrovirals and other common medications is part and parcel of managing patients with HIV/HCV coinfection
  • My Take on the Guidance From AASLD/IDSA for Managing Treatment-Experienced Patients With Genotype 3 HCV Infection and Cirrhosis

    Ira M. Jacobson MD - 11/5/2014 7 comments / Last Comment: 1/25/2015
    When treatment-experienced patients with genotype 3 HCV infection and evidence of advanced liver disease seek care, it’s important to treat them now, even if evidence defining the best regimen is limited.
  • My Take on the Guidance From AASLD/IDSA for Treating PI-Experienced Patients With Genotype 1 HCV Infection

    Norah Terrault MD, MPH - 11/4/2014 2 comments / Last Comment: 1/25/2015
    In this rapidly evolving treatment environment, the best available regimen may not yet have been incorporated into the expert guidance.
  • My Take on the Guidance From AASLD/IDSA for Managing Treatment-Experienced Patients With Genotype 1 HCV Infection and Cirrhosis

    Nezam H. Afdhal MD, FRCPI - 11/4/2014 7 comments / Last Comment: 1/22/2015
    New regimens are becoming available for genotype 1 HCV infection that offer more data and apparently better efficacy than previously recommended regimens in patients with cirrhosis who have experienced previous treatment failure.
  • My Take on the Guidance From AASLD/IDSA for Treating Patients With Genotype 2 HCV Infection

    Norah Terrault MD, MPH - 11/4/2014 6 comments / Last Comment: 1/22/2015
    The AASLD/IDSA HCV guidance is straight forward regarding treatment-naive patients with genotype 2 HCV infection, but there are a few considerations to keep in mind.
  • All-Oral Therapy for HCV: Rewriting the Course of the Disease

    Nancy Reau MD - 11/3/2014 6 comments / Last Comment: 1/16/2015
    All-oral HCV therapies are erasing the importance of traditional obstacles to cure
10 of 43 Shown
Show 10 More